A randomized phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
Phase of Trial: Phase II/III
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Fluorouracil; Gimeracil; Irinotecan; Oteracil; Tegafur
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TRUSTY
- Sponsors Taiho Pharmaceutical
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
- 22 Jun 2017 New trial record